Niagen Bioscience Statistics

Total Valuation

FRA:OCD1 has a market cap or net worth of EUR 444.05 million. The enterprise value is 391.54 million.

Market Cap	444.05M
Enterprise Value	391.54M

Important Dates

The next estimated earnings date is Thursday, March 5, 2026.

Earnings Date	Mar 5, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	80.09M
Shares Outstanding	n/a
Shares Change (YoY)	+10.80%
Shares Change (QoQ)	+0.44%
Owned by Insiders (%)	29.40%
Owned by Institutions (%)	39.95%
Float	52.71M

Valuation Ratios

The trailing PE ratio is 25.50 and the forward PE ratio is 28.39.

PE Ratio	25.50
Forward PE	28.39
PS Ratio	4.18
PB Ratio	7.37
P/TBV Ratio	7.40
P/FCF Ratio	24.64
P/OCF Ratio	24.34
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 21.29, with an EV/FCF ratio of 21.72.

EV / Earnings	22.49
EV / Sales	3.65
EV / EBITDA	21.29
EV / EBIT	23.60
EV / FCF	21.72

Financial Position

The company has a current ratio of 4.12, with a Debt / Equity ratio of 0.04.

Current Ratio	4.12
Quick Ratio	3.22
Debt / Equity	0.04
Debt / EBITDA	0.14
Debt / FCF	0.14
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is 38.90% and return on invested capital (ROIC) is 21.74%.

Return on Equity (ROE)	38.90%
Return on Assets (ROA)	15.60%
Return on Invested Capital (ROIC)	21.74%
Return on Capital Employed (ROCE)	25.59%
Revenue Per Employee	1.02M
Profits Per Employee	167,420
Employee Count	104
Asset Turnover	1.61
Inventory Turnover	3.07

Taxes

In the past 12 months, FRA:OCD1 has paid 701,443 in taxes.

Income Tax	701,443
Effective Tax Rate	3.87%

Stock Price Statistics

The stock price has decreased by -25.69% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-25.69%
50-Day Moving Average	6.00
200-Day Moving Average	7.71
Relative Strength Index (RSI)	43.70
Average Volume (20 Days)	50

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	5.39

Income Statement

In the last 12 months, FRA:OCD1 had revenue of EUR 106.29 million and earned 17.41 million in profits. Earnings per share was 0.20.

Revenue	106.29M
Gross Profit	67.91M
Operating Income	16.45M
Pretax Income	18.11M
Net Income	17.41M
EBITDA	17.11M
EBIT	16.45M
Earnings Per Share (EPS)	0.20

Full Income Statement

Balance Sheet

The company has 54.66 million in cash and 2.60 million in debt, giving a net cash position of 52.06 million.

Cash & Cash Equivalents	54.66M
Total Debt	2.60M
Net Cash	52.06M
Net Cash Per Share	n/a
Equity (Book Value)	60.24M
Book Value Per Share	0.75
Working Capital	60.43M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 18.25 million and capital expenditures -221,598, giving a free cash flow of 18.02 million.

Operating Cash Flow	18.25M
Capital Expenditures	-221,598
Free Cash Flow	18.02M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 63.89%, with operating and profit margins of 15.48% and 16.38%.

Gross Margin	63.89%
Operating Margin	15.48%
Pretax Margin	17.04%
Profit Margin	16.38%
EBITDA Margin	16.10%
EBIT Margin	15.48%
FCF Margin	16.96%

Dividends & Yields

FRA:OCD1 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-10.80%
Shareholder Yield	-10.80%
Earnings Yield	3.92%
FCF Yield	4.06%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:OCD1 has an Altman Z-Score of 13.96 and a Piotroski F-Score of 6.

Altman Z-Score	13.96
Piotroski F-Score	6